Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

CancerVX,TM an OncoEpigenetic DNA Immuno Therapy from World Cancer Institute Targets Female Hormonal Cancers, 5 Other Solid Tumor and 4 Hematological Malignancies and May Become the First Bioactive Personalized Universal Cancer Vaccine

World Cancer Institute Inc.
Posted on: 21 Dec 17

Nathan Sassover, Founder/ CEO of World Cancer Institute Inc., today announced the evolutionary platform of cancer clinical protocols originating initially in 2008 /2009 based on molecular cancer genetics and DNA programmable pharmaceutics to inhibit the growth, replication and proliferation of human cancer cells.

Sassover stated, “CancerVX, (IECT- Intratherapies Epigenetic Cancer Therapeutics) demonstrates progressive immuno-bioactive tumor reduction reflecting broad systemic, tissue and cell level effectiveness. Defined as a combination therapy, CancerVX is comprised of a trivalent compound conjugate conjoining 2 long approved FDA drugs for other indications, augmented by 2 sesqueterpine lactones and their analogue constituents.”

The initial IECT Treatment Protocols were administered to a Stage 3b IBC-Inflammatory Breast Cancer patient, and guided by Medical Advisor, Dr. Brent Treiger, a nationally recognized Oncologist and Cancer Research scientist, with clinical review and assessment of outcome and disease status provided by Slidell Memorial Hospital, New Orleans, and validated by 3 Interpreting Radiologists at Slidell’s onsite MD-Medical Diagnostic Imaging.

CancerVX, which contrary to chemotherapy’s known mechanisms, differentiates itself by reaching the root core and treating the DNA aberrations with altered gene expression for disease modification at the nexus of the mitotic spindle / microtubule chromosomal interface.

This pharmacokinetic impact yields dynamic disease intervention by triangulating for the first time, DNA Demethylation + HDAC/Histone Regulation + NIM/ Neuro Immuno Modulation within a triad of compounds.

Further development and insights for expanded utilization of IECT protocols will be directed to VCX Gene control and P53 reactivation and enhancement as it is frequently mutated in human cancers. CancerVX may catalyze, mediate and possibly control the far reaching adverse effects of the VCX Gene and the restorative potential of augmented P53 function within many types of cancer progression.

More will be announced regarding the pharmaceutic variants of CancerVX (IECT) which emerged during the ensuing 8 years since initial development of this conjoined molecular/ DNA Immunotherapy hybrid in the 2008 initial treatment phase.

The CancerVX protocols are intended for availability only at HealthMedica Health Science Centers affiliated with World Cancer Institute.

CancerVX (IECT) archive and link to additional data, illustrations and extensive photographs of specific CancerVX 8 week Treatment outcome as noted above.

View source version on

Business Wire

Last updated on: 21/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.